Cargando…
Positive relationship between infliximab and adalimumab trough levels at completion of induction therapy with clinical response rates, at a tertiary referral center
BACKGROUND AND AIM: Anti‐tumor necrosis factor alpha (TNFα) therapies have improved outcomes for patients with inflammatory bowel disease. The aim of this study was to explore the relationship between infliximab (IFX) and adalimumab (ADL) trough and antibody levels with clinical response rates at th...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wiley Publishing Asia Pty Ltd
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6207032/ https://www.ncbi.nlm.nih.gov/pubmed/30483525 http://dx.doi.org/10.1002/jgh3.12000 |
_version_ | 1783366470690930688 |
---|---|
author | Tighe, Donal Smith, Sinead O'Connor, Anthony Breslin, Niall Ryan, Barbara McNamara, Deirdre |
author_facet | Tighe, Donal Smith, Sinead O'Connor, Anthony Breslin, Niall Ryan, Barbara McNamara, Deirdre |
author_sort | Tighe, Donal |
collection | PubMed |
description | BACKGROUND AND AIM: Anti‐tumor necrosis factor alpha (TNFα) therapies have improved outcomes for patients with inflammatory bowel disease. The aim of this study was to explore the relationship between infliximab (IFX) and adalimumab (ADL) trough and antibody levels with clinical response rates at the end of induction. METHODS: This was a prospective, single‐center study. Patients were recruited from July 2015 to August 2016. Inclusion criteria were all inflammatory bowel disease patients older than 17 years who started treatment with IFX or ADL. Baseline clinical disease activity indexes were performed. Clinical response was defined as HBI ≤3 or partial Mayo score ≤4% or <30% reduction from baseline. Anti‐TNFα trough and antibody levels were measured using standard ELISA techniques. RESULTS: Thirty‐five patients were recruited, of whom 23 had Crohn's disease and 12 had ulcerative colitis. Eighteen were treated with ADL and 17 with IFX. The mean age of the cohort was 40.3 years, 62.9% were females, 34.3% were on concomitant thiopurines, and 25.7% had prior anti‐TNFα exposure. Overall response rate was 51.4%, 33.3% for ADL and 70.6% for IFX. Mean trough levels were 12.5 μg/mL for IFX and 4.4 μg/mL for ADL. There was a clear link between higher anti‐TNFα trough levels at the end of induction with clinical response rates. For IFX, mean trough level was 16.4 μg/mL for responders versus 5.3 μg/mL for non‐responders (P = 0.026). Area under the curve for association of IFX level at induction with clinical response was 0.864 (P = 0.0001). Similar link was present between higher ADL levels with clinical response, although not statistically significant. CONCLUSION: Higher trough levels at the end of induction are associated with improved response. Ongoing work will define optimal targets at this key timeframe. |
format | Online Article Text |
id | pubmed-6207032 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Wiley Publishing Asia Pty Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-62070322018-11-27 Positive relationship between infliximab and adalimumab trough levels at completion of induction therapy with clinical response rates, at a tertiary referral center Tighe, Donal Smith, Sinead O'Connor, Anthony Breslin, Niall Ryan, Barbara McNamara, Deirdre JGH Open Original Articles BACKGROUND AND AIM: Anti‐tumor necrosis factor alpha (TNFα) therapies have improved outcomes for patients with inflammatory bowel disease. The aim of this study was to explore the relationship between infliximab (IFX) and adalimumab (ADL) trough and antibody levels with clinical response rates at the end of induction. METHODS: This was a prospective, single‐center study. Patients were recruited from July 2015 to August 2016. Inclusion criteria were all inflammatory bowel disease patients older than 17 years who started treatment with IFX or ADL. Baseline clinical disease activity indexes were performed. Clinical response was defined as HBI ≤3 or partial Mayo score ≤4% or <30% reduction from baseline. Anti‐TNFα trough and antibody levels were measured using standard ELISA techniques. RESULTS: Thirty‐five patients were recruited, of whom 23 had Crohn's disease and 12 had ulcerative colitis. Eighteen were treated with ADL and 17 with IFX. The mean age of the cohort was 40.3 years, 62.9% were females, 34.3% were on concomitant thiopurines, and 25.7% had prior anti‐TNFα exposure. Overall response rate was 51.4%, 33.3% for ADL and 70.6% for IFX. Mean trough levels were 12.5 μg/mL for IFX and 4.4 μg/mL for ADL. There was a clear link between higher anti‐TNFα trough levels at the end of induction with clinical response rates. For IFX, mean trough level was 16.4 μg/mL for responders versus 5.3 μg/mL for non‐responders (P = 0.026). Area under the curve for association of IFX level at induction with clinical response was 0.864 (P = 0.0001). Similar link was present between higher ADL levels with clinical response, although not statistically significant. CONCLUSION: Higher trough levels at the end of induction are associated with improved response. Ongoing work will define optimal targets at this key timeframe. Wiley Publishing Asia Pty Ltd 2017-09-18 /pmc/articles/PMC6207032/ /pubmed/30483525 http://dx.doi.org/10.1002/jgh3.12000 Text en © 2017 The Authors. JGH Open: An open access journal of gastroenterology and hepatology published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Articles Tighe, Donal Smith, Sinead O'Connor, Anthony Breslin, Niall Ryan, Barbara McNamara, Deirdre Positive relationship between infliximab and adalimumab trough levels at completion of induction therapy with clinical response rates, at a tertiary referral center |
title | Positive relationship between infliximab and adalimumab trough levels at completion of induction therapy with clinical response rates, at a tertiary referral center |
title_full | Positive relationship between infliximab and adalimumab trough levels at completion of induction therapy with clinical response rates, at a tertiary referral center |
title_fullStr | Positive relationship between infliximab and adalimumab trough levels at completion of induction therapy with clinical response rates, at a tertiary referral center |
title_full_unstemmed | Positive relationship between infliximab and adalimumab trough levels at completion of induction therapy with clinical response rates, at a tertiary referral center |
title_short | Positive relationship between infliximab and adalimumab trough levels at completion of induction therapy with clinical response rates, at a tertiary referral center |
title_sort | positive relationship between infliximab and adalimumab trough levels at completion of induction therapy with clinical response rates, at a tertiary referral center |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6207032/ https://www.ncbi.nlm.nih.gov/pubmed/30483525 http://dx.doi.org/10.1002/jgh3.12000 |
work_keys_str_mv | AT tighedonal positiverelationshipbetweeninfliximabandadalimumabtroughlevelsatcompletionofinductiontherapywithclinicalresponseratesatatertiaryreferralcenter AT smithsinead positiverelationshipbetweeninfliximabandadalimumabtroughlevelsatcompletionofinductiontherapywithclinicalresponseratesatatertiaryreferralcenter AT oconnoranthony positiverelationshipbetweeninfliximabandadalimumabtroughlevelsatcompletionofinductiontherapywithclinicalresponseratesatatertiaryreferralcenter AT breslinniall positiverelationshipbetweeninfliximabandadalimumabtroughlevelsatcompletionofinductiontherapywithclinicalresponseratesatatertiaryreferralcenter AT ryanbarbara positiverelationshipbetweeninfliximabandadalimumabtroughlevelsatcompletionofinductiontherapywithclinicalresponseratesatatertiaryreferralcenter AT mcnamaradeirdre positiverelationshipbetweeninfliximabandadalimumabtroughlevelsatcompletionofinductiontherapywithclinicalresponseratesatatertiaryreferralcenter |